In this study, vehicle-treated PD models, in which microglia were challenged, showed upregulation of LRRK2 expression, but this phenomenon was inhibited by C16, Ang-1, and especially the combination therapy, which may be due to the decreased number of inflammatory cells caused by these treatments. The gene discussed is ANGPT1; the disease is Parkinson disease.